Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program
Open Access
- 3 January 2013
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 121 (1), 197-206
- https://doi.org/10.1182/blood-2012-03-417667
Abstract
Although peripheral blood stem cells (PBSCs) have replaced bone marrow (BM) as the most common unrelated donor progenitor cell product collected, a direct comparison of concurrent PBSC versus BM donation experiences has not been performed. We report a prospective study of 2726 BM and 6768 PBSC donors who underwent collection from 2004 to 2009. Pain and toxicities were assessed at baseline, during G-CSF administration, on the day of collection, within 48 hours of donation, and weekly until full recovery. Peak levels of pain and toxicities did not differ between the 2 donation processes for most donors. Among obese donors, PBSC donors were at increased risk of grade 2 to 4 pain as well as grade 2 to 4 toxicities during the pericollection period. In contrast, BM donors were more likely to experience grade 2 to 4 toxicities at 1 week and pain at 1 week and 1 month after the procedure. BM donors experienced slower recovery, with 3% still not fully recovered at 24 weeks, whereas 100% of PBSC donors had recovered. Other factors associated with toxicity included obesity, increasing age, and female sex. In summary, this study provides extensive detail regarding individualized risk patterns of PBSC versus BM donation toxicity, suggesting donor profiles that can be targeted with interventions to minimize toxicity.Keywords
This publication has 22 references indexed in Scilit:
- Unrelated hematopoietic stem cell donors as research subjectsBone Marrow Transplantation, 2010
- Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerationsBone Marrow Transplantation, 2010
- Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor ProgramBlood, 2009
- Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor ProgramTransplantation and Cellular Therapy, 2008
- An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allograftingTransplantation and Cellular Therapy, 2004
- Differences between graft product and donor side effects following bone marrow or stem cell donationBone Marrow Transplantation, 2003
- Impact of stem cell donation modality on normal donor quality of life: a prospective randomized studyBone Marrow Transplantation, 2003
- Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaintsBone Marrow Transplantation, 2002
- Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomised studyBone Marrow Transplantation, 2002
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958